Female Sexual Arousal Disorder

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Palatin Technologies
1 program
1
bremelanotidePhase 2Peptide1 trial
Active Trials
NCT01382719CompletedEst. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Palatin Technologiesbremelanotide

Clinical Trials (1)

NCT01382719Palatin Technologiesbremelanotide

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Start: Jun 2011Est. completion: Sep 2012
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space